Zoetis - ZTS Stock Forecast, Price & News

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Analyst Ratings Changes

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus decreased their price objective on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating on the stock in a research report on Friday, June 24th. The Goldman Sachs Group decreased their price objective on shares of Zoetis from $208.00 to $202.00 and set a "buy" rating on the stock in a research report on Thursday, July 21st. William Blair reiterated an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. Piper Sandler started coverage on shares of Zoetis in a research report on Monday, July 11th. They set an "overweight" rating and a $205.00 price target on the stock. Finally, StockNews.com cut shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Tuesday, April 26th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $224.14.

Zoetis Price Performance

Zoetis stock opened at $173.18 on Friday. The firm has a 50-day moving average price of $171.96 and a 200-day moving average price of $180.76. The firm has a market capitalization of $81.07 billion, a PE ratio of 39.27, a price-to-earnings-growth ratio of 2.89 and a beta of 0.73. The company has a current ratio of 2.18, a quick ratio of 1.46 and a debt-to-equity ratio of 1.14. Zoetis has a 12-month low of $154.18 and a 12-month high of $249.27.

Zoetis (NYSE:ZTS - Get Rating) last posted its earnings results on Thursday, August 4th. The company reported $1.20 EPS for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). The business had revenue of $2.10 billion for the quarter, compared to analysts' expectations of $2.03 billion. Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The company's revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the business posted $1.19 EPS. As a group, equities research analysts forecast that Zoetis will post 5.01 EPS for the current year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 1st. Shareholders of record on Thursday, July 21st will be paid a dividend of $0.325 per share. This represents a $1.30 annualized dividend and a yield of 0.75%. The ex-dividend date is Wednesday, July 20th. Zoetis's payout ratio is 29.48%.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 2,167 shares of the business's stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the sale, the executive vice president now owns 23,687 shares of the company's stock, valued at approximately $4,269,818.62. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, CEO Kristin C. Peck sold 311 shares of the company's stock in a transaction dated Thursday, July 7th. The shares were sold at an average price of $180.00, for a total value of $55,980.00. Following the completion of the sale, the chief executive officer now owns 39,743 shares of the company's stock, valued at $7,153,740. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Roxanne Lagano sold 2,167 shares of the company's stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the sale, the executive vice president now directly owns 23,687 shares of the company's stock, valued at approximately $4,269,818.62. The disclosure for this sale can be found here. Insiders sold a total of 18,356 shares of company stock worth $3,250,158 in the last three months. Company insiders own 0.12% of the company's stock.